ArticleJACC. Asia2026
Efficacy and Safety of Quarterly Dosing SHR-1918 in Patients With Suboptimally Controlled Hyperlipidemia.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06471218 (Evaluation of the Efficacy and Safety of Multiple Subcutaneous Injections of SHR-1918 in Patients With Hyperlipidemia in Poor Control), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Efficacy and Safety of Multiple Subcutaneous Injections of SHR-1918 in Patients With Hyperlipidemia in Poor Control: a Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trials
Who cites it
1 citing paper in PubMed.
- Quarterly SHR-1918: End-of-Interval Activity-But for Whom?JACC. Asia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSHR-1918 is a long-acting angiopoietin-like 3 antibody with established lipid-lowering efficacy at 600 mg once every 4 weeks or once every 8 weeks.
objectivesThis randomized, double-blind, placebo-controlled study assessed the efficacy and safety of SHR-1918 at an extended dosing interval (once every 12 weeks) in patients with hyperlipidemia.
methodsPatients who did not achieve their low-density lipoprotein cholesterol (LDL-C) targets after statin run-in were randomized (2:1) to receive subcutaneous SHR-1918 (600 or 1,200 mg) or placebo once every 12 weeks for 24 weeks. The primary endpoint was percent change in LDL-C from baseline to week 24.
resultsForty-four patients were randomized to SHR-1918 600 mg (n = 14), SHR-1918 1,200 mg (n = 16), or placebo (n = 14). At week 24, the percent change in LDL-C from baseline was -20.8% (95% CI: -28.4 to -13.1), -25.1% (95% CI: -32.4 to -17.7), and -2.2% (95% CI: -10.1 to 5.7) in the 3 groups, respectively. The between-group difference (SHR-1918 vs placebo) was -18.6% (95% CI: -29.5 to -7.6; P = 0.0015) for 600 mg and -22.9% (95% CI: -33.7 to -12.1; P = 0.0001) for 1,200 mg. The percent change in triglyceride was -49.8% (95% CI: -61.7 to -37.9) and -58.8% (95% CI: -70.3 to -47.3) with SHR-1918 600 mg and 1,200 mg compared with -1.2% (95% CI: -13.6 to 11.2) with placebo, showing between-group differences of -48.6% (95% CI: -65.8 to -31.4; P < 0.0001) and -57.6% (95% CI: -74.6 to -40.6; P < 0.0001).
conclusionsSHR-1918, at a once every 12 weeks dosing frequency, further reduced LDL-C and triglyceride levels in hyperlipidemic patients inadequately controlled with background lipid-lowering therapies. (Evaluation of the Efficacy and Safety of Multiple Subcutaneous Injections of SHR-1918 in Patients With Hyperlipidemia in Poor Control; NCT06471218).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.